Research programme: ERRa-inhibitor based breast cancer therapeutics - Lead Pharma

Drug Profile

Research programme: ERRa-inhibitor based breast cancer therapeutics - Lead Pharma

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lead Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ERRalpha estrogen-related receptor-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 21 Nov 2017 Research programme: breast cancer therapeutics - Lead Pharma is available for licensing as of 21 Nov 2017.
  • 21 Nov 2017 Preclinical trials in Breast cancer in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top